Creyon Bio
Biotechnology company utilizing AI and machine learning to design and develop programmable medicines, including next-generation gene therapies and nucleic acid therapeutics.
Website
https://www.creyonbio.comLocation
San Diego, California, USA
Founded
2020
Investors
1
Categories
ai-ml, therapeutics, biotech, drug-discovery, gene-therapy, programmable-medicines
Notes
Creyon Bio is a biotechnology company leveraging artificial intelligence and machine learning to design programmable medicines. The company's computational platform enables the development of next-generation gene therapies and nucleic acid-based therapeutics with optimized safety and efficacy profiles.
By combining advanced computational biology with synthetic biology approaches, Creyon Bio aims to accelerate the development of precision medicines that can be programmed to address specific disease mechanisms.
Team
- Joseph Higgins, Ph.D. - Co-founder & Chief Executive Officer
- LinkedIn: linkedin.com/in/josephhiggins
Additional Research Findings
- Backed by Alexandria Venture Investments
- AI/ML-powered drug design platform
- Focus on programmable medicines
- Gene therapy and nucleic acid therapeutics
- Computational biology approach
- San Diego, California headquarters
- Next-generation therapeutic modalities
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Alexandria Venture Investments | Pasadena, USA | cvc | seedseries-a+3 | 6 |